1. Extended Pleurectomy-Decortication–Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years 
Joseph S. Friedberg, MD, Charles B. Simone, MD, Melissa J. Culligan, RN, MS, Andrew R. Barsky, BS, Abigail Doucette, MPH, Sally McNulty, RN, Stephen M. Hahn, MD, Evan Alley, MD, PhD, Daniel H. Sterman, MD, Eli Glatstein, MD, Keith A. Cengel, MD, PhD 
The Annals of Thoracic Surgery 
Volume 103, Issue 3, Pages (March 2017)
DOI: /j.athoracsur
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Survival analysis of entire 73-patient cohort, overall survival (OS [dark gray line]) and progression-free survival (PFS [light gray line]).
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Effect of lymph node metastases on (A) survival and (B) progression-free survival. Analysis of the effect of lymph node metastases was performed, with patients grouped as either node negative (N0 [dark gray lines]) or node positive (N1 or N2 [light gray lines]). Overall survival for patients with lymph node metastases was 7.3 ± 0.16 years and for patients without lymph node metastases, it was 1.9 ± 0.5 years. Progression-free survival for patients with lymph node metastases was 2.2 ± 1.1 years, and for patients without lymph node metastases, it was 0.8 ± 0.1 years.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
Effect of first treatment failure site on (A) overall survival and (B) progression-free survival. Analysis of patterns of initial treatment failure was performed, with patients grouped as having initial recurrence involving (1) locoregional sites (light gray lines) or (2) distant with or without locoregional sites (dark gray lines). Overall survival for patients with initial treatment failure at only locoregional sites was 2.7 ± 0.9 years; for distant failure with or without locoregional sites, it was 1.9 ± 0.9 years. Progression-free survival for patients having only locoregional recurrence was 1.0 ± 0.3 years, and for patients having distant recurrence with or without locoregional recurrence, it was 1.0 ± 0.2 years.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions